Solstice Neurosciences responds to FDA early communication regarding Myobloc for cervical dystonia Feb. 12, 2008
Activation of the unfolded protein response central in the pathogenesis of Charcot-Marie-Tooth 1B Feb. 12, 2008
Transdel submits to FDA phase III clinical study proposal for Ketotransdel in acute pain Feb. 11, 2008
RSS